Kiniksa Pharmaceuticals International (KNSA) Income towards Parent Company (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Income towards Parent Company for 10 years, with the latest figure at $22.6 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 164.57% year-over-year to $22.6 million; the trailing twelve-month figure through Mar 2026 stood at $73.1 million (up 887.6% YoY), and the FY2025 full-year result was $59.0 million, up 266.12% from the prior year.
• Income towards Parent Company for Q1 2026 stood at $22.6 million, up from $14.2 million in the prior quarter.
• The five-year high for Income towards Parent Company was $224.1 million in Q3 2022, with the low at -$90.6 million in Q4 2022.
• Historically, Income towards Parent Company has averaged $2.4 million across 5 years, with a median of -$3.9 million in 2024.
• Annual changes were most pronounced in 2024 — Income towards Parent Company slumped 126.1% — and 2025, when it soared 1269.6%.
• Kiniksa Pharmaceuticals International's Income towards Parent Company stood at -$90.6 million in 2022, then rose by 8.39% to -$83.0 million in 2023, then surged by 98.54% to -$1.2 million in 2024, then soared by 1269.6% to $14.2 million in 2025, then surged by 59.11% to $22.6 million in 2026.
• The last three Income towards Parent Company figures came in at $22.6 million (Q1 2026), $14.2 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.